Stevanato Group Q2 2026: Revenue Up 8%, Adjusted EBITDA Margin Expands to 26%, but Net Profit Hit by Subsidiary Sale Loss and Higher Taxes
STVN sits 52% above its 52-week low of $12.89 on elevated volume (2.7× avg).
Summary
Stevanato Group's Q2 2026 revenue grew 8% to €302M, with adjusted EBITDA margin expanding to 26%. Reported net profit fell 23% due to a €12.2M loss on a subsidiary sale and a higher tax rate. Material weaknesses in internal controls persist.
Key Events · Earnings and Guidance · STVN
-
Q2 Revenue Up 8%, Adjusted EBITDA Margin at 26%
Revenue reached €302.0M, up 7.8% YoY (8.2% constant currency), driven by high-value solutions. Adjusted EBITDA rose 20.9% to €78.7M, with margin expanding to 26.0% from 23.2% a year ago.
-
Net Profit Hit by €12.2M Subsidiary Sale Loss
Reported net profit fell 22.7% to €23.0M, largely due to a €12.2M loss on the sale of Balda C. Brewer Inc. and related transaction costs. Adjusted net profit was €37.6M, or €0.14 per diluted share.
-
Effective Tax Rate Jumps to 34.1%
The effective tax rate increased from 24.3% in H1 2025 to 34.1% in H1 2026, driven by the loss of a 4% IRES premiale benefit for the Italian subsidiary and the non-deductibility of the subsidiary sale loss.
-
Material Weaknesses in Internal Controls Remain
The company disclosed that material weaknesses in internal control over financial reporting, first reported in the 2025 20-F, remain unremediated as of June 30, 2026. Remediation efforts are ongoing.
Analysis · STVN · Industrial Applications And Services
Stevanato Group delivered solid top-line growth in Q2 2026, with revenue rising 8% to €302 million driven by high-value solutions like syringes and EZ-fill vials. Adjusted EBITDA margin improved to 26%, reflecting operational leverage and cost discipline. However, reported net profit fell 23% due to a €12.2 million loss on the sale of Balda C. Brewer Inc. and a higher effective tax rate (34.1% vs 24.3%) as the company lost a favorable Italian tax regime and the subsidiary sale loss was non-deductible. The balance sheet shows rising net debt and lower cash, partly from heavy capex for capacity expansion. Critically, material weaknesses in internal controls remain unremediated, a governance red flag that warrants close attention.
At the time of this filing, STVN was trading at $19.65 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $12.89 to $28.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.